Expedeon AG signs commercial agreement with Sona Nanotech
Agreement will address limitations in development of multiplex point-of-care Lateral Flow Assay diagnostic tests
Expedeon AG and Sona Nanotech Inc. (“Sona”), today announced they have entered into a commercial agreement to address limitations in development of complex, multiplex point-of-care (POC) lateral flow assay (LFA) diagnostic tests.